IC Memo — AbbVie (Ballast Seed)

Condensed from the full IC memo. Full memo: deliverables/2026-07-11-seed/IC_Memo_ABBV.docx

Action: Seed an 8.0% Ballast position in ABBV (≈$80,000 on the fund's $1.0mm NAV; ≈323 shares at the live price) — this is the fund's IPS position cap, so ABBV is seeded at the maximum, not below it. Benchmark SCHD.

Dividend durability. AbbVie is tracked as one of the longest-running dividend-growth stories in large-cap pharma: approximately 52 consecutive years of increases counting predecessor Abbott Laboratories' pre-2013 history (approximate, analyst recall — no live dividend feed was available this session). GAAP payout has at times been distorted well above 100% by non-cash acquisition-related charges (Allergan-deal amortization/impairments); on an adjusted free-cash-flow basis, coverage has historically been comfortable — FCF in the high-teens-to-low-$20B range annually against a dividend cash outlay roughly half that (approximate FY2023–FY2024 figures), i.e., FCF payout near 45–55%.

Post-Humira transition. Humira lost US exclusivity in January 2023, opening biosimilar competition and driving a well-flagged multi-year decline in what had been the best-selling drug globally. The replacement engine is Skyrizi (risankizumab, initial 2019 approval, since expanded across psoriatic arthritis, Crohn's, and ulcerative colitis) and Rinvoq (upadacitinib, initial 2019 approval, similarly expanded). Management guidance communicated around 2023–2024 investor events (approximate dating, not re-verified live) called for combined Skyrizi + Rinvoq sales to exceed Humira's historical peak by roughly 2027 — the next one to two reported quarters should be checked against that path before adding to the position.

Rate sensitivity. High-payout, low-beta names like ABBV carry a partial "bond proxy" character — valuation is sensitive to long-duration Treasury yields. This seed cycle's own regime read (same data pull, see Seeding-Day Regime Memo) showed TLT trading ~1.03% below its trailing 50-session mean — a mild downtrend in long-duration Treasury prices, i.e., yields drifting modestly higher into the seed date. That's a mild relative headwind for bond-proxy equities, not thesis-breaking at this magnitude, but it argues for sizing at (not above) plan.

Key risks: franchise durability beyond Skyrizi/Rinvoq (both have their own eventual loss-of-exclusivity dates), and US drug-pricing/policy risk (Medicare negotiation under the IRA) — sector-wide, not AbbVie-specific.

Exit plan. Per Ballast IPS: fund-level −10% drawdown-from-high-water trigger freezes new buys pending a de-risk review; monthly income/beta report (target β ≤0.75). Name-specific triggers: a dividend freeze/cut, Skyrizi+Rinvoq growth falling meaningfully short of the guided hand-off path, or a sustained sharp back-up in long yields re-rating bond-proxy equities lower sector-wide. Since the position is seeded at the fund's 8% cap, any accumulation plan requires a re-underwrite memo, not a routine add.